Vol. 3, Issue 3, Part E (2019)

Author(s): Alp Yildiz and Aybala Yildiz

Abstract: Few data are available to evaluate health-related quality of life of people with irritable bowel syndrome (IBS) and fewer data are available for anxiety and depression status in this patients. Additionally we now know that fibromiyalgia and IBS is different expressions of same process. 114 patients with IBS according to Rome IV criteria included the study. All patients has given 40 mg otilonium bromide-80 mg simeticone combination drug in one tablet 3 times a day on meal time. Qol questionnaire (QoL), beck anxiety index (BAI), Hamilton depression index (HDI) and Fibromiyalgia symptom severity index (FMSS) applied before the treatment and after the treatment on follow-up at 3rd month. 64 patients of 114 showed complete recovery for both ibs and fibromyalgia after treatment (%56.14). In the symptomatic treatment of Irritable Bowel Disease co-excistent with fibromyalgia, a major treatment alternative since being scientifically proven for their effectiveness for many years, Otilonium Bromide and Simethicone's single tablet feature improves patient compliance of IBS patients and leads to improve the quality of life of IBS patients.